Latest News from "The Pink Sheet" DAILY - Cephalon Looks For Growth As Nuvigil Fails Schizophrenia Trial

Arena Gets Financing Boost, Lorcaserin Advisory Committee Date

Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.   read more

 

Cephalon Looks For Growth as Nuvigil Fails Schizophrenia Trial

With sales leader Provigil slated to lose patent protection in 2012, specialty pharma also is looking beyond Nuvigil for answers.   read more

 

Orphan Drugs In The House: Reps. Crowley, Upton Form Rare Disease Caucus

The congressmen are expected to issue a "Dear Colleague" letter soon inviting other House members to join in raising awareness of rare diseases and orphan drug development.   read more

 

Prolia Pricing: A High Bar For Osteoporosis But Room To Tap Oncology Potential

With a wholesale acquisition cost of $1,650 a year for Prolia, Amgen has effectively sacrificed the first-line treatment market for osteoporosis in favor of long-term potential in future indications.   read more

 

In Initial Assessments, NICE Recommends Celgene's Thalidomide And J&J's Bortezomib

Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here